Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...
Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...
A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...
An analysis of reports from phase III trials (published between 2011 and 2013) investigating patients with solid tumours found widespread failings in both the conduct and reporting of subgroup ...
Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...
One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors?
Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...
Nerandomilast slowed FVC decline in US IPF patients compared to placebo, with a favorable safety profile and tolerability. The FIBRONEER-IPF trial was a double-blind, placebo-controlled study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results